Two 12-week phase 3 trials and a 43-week extension will test 8 mg and 16 mg HLP003 added to antidepressants, with APPROACH enrollment now complete.
|Articles|September 16, 2008
- December15 2003
- Volume 10
- Issue 23
Pharmaceutical Stock Watch
Advertisement
Articles in this issue
about 18 years ago
Prevent Vacation Home Flood Calamitiesabout 18 years ago
Get the Attention of Top Money Managersabout 18 years ago
Is Your Medical Practice in Jeopardy?about 18 years ago
10 Web Site Tips to Improve Your Practiceabout 18 years ago
Should You Be Concerned with the AMT?about 18 years ago
Wealth Preservation: Protect Your Treasuresabout 18 years ago
Other Valuable Toolsabout 18 years ago
Make Sense of the Mutual Fund Scandalabout 18 years ago
Survive the Mutual Fund Fiascoabout 18 years ago
Discover the Scandal Behind the ScandalAdvertisement
Related to this article
This preview of EADV 2026 provides a teaser of new data and interviews being highlighted at this Vienna dermatology conference.
Phase 2b AMPLIFIED data show a 42.7% UACR drop in AMKD with modest proteinuria; AMPLITUDE interim data are due early 2027.
George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.
Advertisement
Advertisement
Trending on HCPLive
1
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
2
ProACt Data Show Early Functional Gains with Adjunctive Cariprazine In MDD
3
FDA Updates Sotatercept Label with HYPERION Data in Early PAH
4
EMBARQ-CSU: Barzolvolimab Meets Primary, Secondary Endpoints in CSU Trials
5